Understanding Checkpoint Inhibitors in NSCLC

Activity Overview

This 15-minute infographic activity uses an interactive approach augmented by a whiteboard animation and clinician videos to delineate checkpoint inhibitor mechanisms of action, key safety points, and important aspects of patient counseling.

0.25 CE Credit(s)
Expires: June 24, 2022

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Assess the relationship between checkpoint inhibitor mechanism of action and differential safety profile versus chemotherapy


Activity Faculty


Ahmet Sezer, MD

Professor, Medical Oncology
Başkent University
Adana, Turkey

Head Shot YMS2312_0228_Goldberg (2)

Sarah B. Goldberg, MD, MPH

Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT

Brian Henick

Brian Henick, MD

Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY